POPULARITY
Categories
15 episodes with drug administration fda
26 episodes with drug administration fda
32 episodes with drug administration fda
35 episodes with drug administration fda
16 episodes with drug administration fda
19 episodes with drug administration fda
12 episodes with drug administration fda
7 episodes with drug administration fda
8 episodes with drug administration fda
8 episodes with drug administration fda
11 episodes with drug administration fda
6 episodes with drug administration fda
7 episodes with drug administration fda
7 episodes with drug administration fda
5 episodes with drug administration fda
9 episodes with drug administration fda
13 episodes with drug administration fda
4 episodes with drug administration fda
6 episodes with drug administration fda
5 episodes with drug administration fda
5 episodes with drug administration fda
16 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
3 episodes with drug administration fda
5 episodes with drug administration fda
6 episodes with drug administration fda
7 episodes with drug administration fda
4 episodes with drug administration fda
10 episodes with drug administration fda
3 episodes with drug administration fda
5 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
11 episodes with drug administration fda
3 episodes with drug administration fda
3 episodes with drug administration fda
5 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
4 episodes with drug administration fda
2 episodes with drug administration fda
2 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
The Context of White Supremacy hosts the Counter-Racist Weekly Review 05/30/26. This broadcast examines current events from across the globe to learn what's happening in all areas of people activity. We cultivate Counter-Racist Media Literacy by scrutinizing journalists' word choices and using logic to deconstruct what is reported as "news." We'll use these sessions to hone our use of terms as tools to reveal truth, neutralize Racists/White people. #ANTIBLACKNESS This week, we analyze the ongoing enforcement of racial terror and state policy: 1. Direct Racist Violence and Neighborhood Vandalism: We examine a disturbing series of direct, racially motivated property attacks and terror tactics aimed at Black people. This includes the arrest of a 13-year-old charged with hate crimes for vandalism in Central, Louisiana, a targeted attack on a Black family's home in Farmington Hills, Michigan, and explicit white supremacist graffiti left on a residential street in Slidell, Louisiana. We analyze how these cross-generational actions function to enforce fear and maintain racial terror in Black spaces. 2. The Vape Industry's New Target: We investigate reports that senior regulators within the Food and Drug Administration (FDA) were completely blindsided by policy maneuvers opening the market to unauthorized, fruit-flavored e-cigarettes. We examine the corporate strategy behind these new products—including new fruit-flavored options—and the systemic implications for non-white children who will likely bear the brunt of these predatory marketing tactics. 3. Biometric Surveillance and Ocular Cataloging: We dissect a massive $25 million no-bid contract finalized by ICE to flood the streets with over 1,500 handheld, smartphone-based iris scanners. We scrutinize the expansion of this biometric database, analyzing how this BI2 Tech acts as a digital dragnet targeting non-white oculars during field operations. Furthermore, we question the broader scope of this surveillance infrastructure, examining the very real threat of these tools being weaponized to scan the eyeballs of non-white protesters and US citizens under the guise of state security. #EndStageWhiteSupremacy #COINTELPRO #TheRedboneDeception #TheCOWS17Years INVEST in The COWS – [http://paypal.me/TheCOWS](http://paypal.me/TheCOWS) Cash App: [https://cash.app/$TheCOWS](https://cash.app/$TheCOWS) CALL IN NUMBER: 720.716.7300 CODE 564943#
In this episode of the Ageless Future Podcast, Cade Archibald explores emerging research around MUSE cells and their potential role in regenerative wellness and cellular recovery. He discusses how researchers believe these cells may respond to signals from damaged tissue, support the body's natural cleanup processes, and contribute to ongoing studies in areas such as brain health, heart health, and healthy aging. Cade also shares perspectives on lifestyle habits that may support overall wellness, including sleep, movement, and nutrition, while highlighting the growing interest in personalized approaches to recovery and resilience.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this heartfelt episode of John Solomon Reports, we take a moment to honor the brave heroes of our nation—our veterans and the police officers who have served both on the battlefield and in our communities. John Solomon emphasizes the sacrifices made by those who defended our freedoms over the past 250 years, particularly focusing on the challenges faced by wounded veterans now left without a safety net. He introduces the Wounded Blue, an organization dedicated to supporting injured officers who have been abandoned by their departments due to injuries sustained in the line of duty.The episode features Congressman Chip Roy of Texas, who shares his insights on the upcoming Texas Attorney General race and discusses new legislation that could impact the state. As the show progresses, John shifts focus to the Food and Drug Administration (FDA), examining its current challenges and the urgent need for reform. Senator Roger Marshall, a practicing physician, and Dr. David Gortler, a former FDA regulator, provide critical perspectives on the agency's operations and the implications for public health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Guest: Barry Quart, CEO and DirectorCompany: Connect Biopharma, NASDAQ:CNTBWebsite: https://www.connectbiopharma.com/Connect Biopharma Bio:Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.Barry Quart Bio:Dr. Barry Quart brings over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. He has personally led several early-stage biotech companies through late-stage clinical development, regulatory strategy, highlighted by nine U.S. Food and Drug Administration (FDA) approved drugs.Dr. Quart was most recently CEO at Heron Therapeutics. He first served as CEO and Director starting 2012, transitioned to President and CEO in 2019 and was named Chair of the Board in October 2020. At Heron, Dr. Quart oversaw the development and approval of four drugs: two drugs for CINV (CINVANTI® and SUSTOL®) and two acute care drugs (ZYNRELEF® and APONVIE®). Prior to Heron, Dr. Quart co-founded Ardea Biosciences, Inc. in 2006 and served as its President and Chief Executive Officer and Director from its inception through its acquisition by AstraZeneca PLC in 2012. At Ardea, Dr. Quart invented and oversaw the development of a drug for gout (ZURAMPIC®), as well as the design and development of a series of MEK inhibitors for cancer that were licensed to Bayer AG. Dr. Quart currently serves on the Board of Directors of Kiniksa Pharmaceuticals. He is an inventor on 18 U.S. patents and an author on 75 publications and abstracts. Dr. Quart received his Pharm.D. from the University of California, San Francisco.
In this episode, the host introduces Muse cells, a recently identified subset of naturally occurring reparative cells associated with stem cell research and regenerative science. The discussion explains how these cells are found within tissues like bone marrow and umbilical cord sources, and how researchers are working to isolate and study their unique properties, including their responsiveness to signals related to stress or tissue damage. The conversation also highlights ongoing areas of investigation—such as neurology, orthopedics, and cardiovascular research—while emphasizing that much of the current understanding is still emerging. Overall, the episode presents Muse cells as a developing area of interest within the broader field of regenerative medicine and longevity-focused research.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this presentation, Cade Archibald discusses the rapid growth of peptides and the increasing confusion surrounding their sourcing, regulation, and quality. He explains the distinction between regulated compounding pharmacies (such as 503A and 503B) and the rise of “research use only” (RUO) peptides, which are often marketed online without clear oversight or verification. Cade highlights concerns around inconsistent labeling, uncertain origins, and potential quality issues in the unregulated market, while emphasizing the importance of working with licensed professionals and verified pharmacies. He also outlines recent FDA categorization changes, ongoing reviews of certain peptides, and the broader regulatory environment shaping access and availability. Overall, the talk encourages listeners to be discerning, prioritize transparency and professional guidance, and understand the evolving landscape before making decisions.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a slew of advances in diabetes technology and treatments, starting with the US Food and Drug Administration (FDA)'s recent approval of the Tandem automated insulin delivery system for use during pregnancy in individuals with type 1 diabetes. The conversation centers on findings from the CIRCUIT trial, which demonstrated significant improvements in time in range among pregnant patients, a population historically challenging to manage because of stringent glycemic targets. Isaacs and Bellini review practical considerations from the study, including the use of continuous sleep mode to target tighter glucose ranges and proactive optimization of basal rates, correction factors, and carbohydrate ratios to improve outcomes. They emphasize that FDA approval now allows clinicians and manufacturers to openly discuss evidence-based best practices for pregnancy management using automated insulin delivery systems.The hosts also highlight the importance of clinician comfort with aggressive insulin automation during pregnancy, noting that increased basal modulation, suspensions, and automated adjustments should be expected as physiologic insulin needs fluctuate throughout gestation. Bellini stresses the importance of reducing patient burden while maintaining intensive glycemic management, tying this theme into Tandem's newly announced compatibility with the Dexcom G7 15-day sensor. Both hosts note strong patient enthusiasm for extending sensor wear time, framing reduced device maintenance as an important quality-of-life improvement even when the practical change appears modest.The discussion then shifts to immunotherapy in type 1 diabetes, focusing on the expanded approval of teplizumab to include children as young as 1 year old for delaying progression from stage 2 to stage 3 disease. Isaacs and Bellini underscore how broader eligibility may strengthen adoption of autoantibody screening among relatives of patients with type 1 diabetes. They review evidence showing that screening substantially lowers rates of diabetic ketoacidosis at diagnosis and discuss the broader clinical significance of delaying symptomatic disease onset, even when delays are shorter than the median duration reported in trials. The hosts note that many families value the possibility of a more gradual transition into insulin dependence, often requiring only minimal insulin therapy initially rather than presenting with severe metabolic decompensation.The conversation also addresses ongoing regulatory developments surrounding teplizumab for newly diagnosed stage 3 type 1 diabetes. Although the anticipated expedited review pathway has been withdrawn, the hosts remain optimistic about eventual approval, citing encouraging data and the growing role of precision medicine approaches in identifying patients most likely to benefit from immune intervention.To conclude the episode, Isaacs and Bellini examine a post hoc analysis from the SURMOUNT-5 trial comparing tirzepatide and semaglutide in adults with obesity and prediabetes. They discuss findings showing high rates of reversion to normoglycemia in both treatment groups, with tirzepatide demonstrating greater efficacy overall. The hosts frame these data within the broader movement to reconceptualize prediabetes as an earlier stage of type 2 diabetes and cardiovascular disease risk rather than a benign precursor state. They emphasize the potential value of earlier therapeutic intervention to prevent progression and reduce long-term cardiometabolic complications while also acknowledging the importance of maintaining multiple treatment options because of variability in medication tolerability and patient response.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Tandem Diabetes Care. Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes. April 27, 2026. Accessed May 8, 2026. https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-cares-control-iq-automated-insulin-delivery2: Sanofi. Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. April 22, 2026. Accessed May 8, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-32786503: Galindo RJ, Aronne LJ, Horn DB, et al. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. J Endocrinol Invest. Published online April 20, 2026. doi:10.1007/s40618-026-02895-3
In this conversation, Cade Archibald sits down with inventor and author John Jaquish, PhD to discuss his background in fitness-adjacent tech and why he believes “variable resistance” training changes how people think about workouts. They trade perspectives on popular biohacking topics—like peptides, appetite control, and testosterone products—while emphasizing personal experimentation, training mechanics, and the challenges of separating hype from real-world outcomes. Along the way, Jaquish shares the origin story behind his projects (including OsteoStrong and X3), describes the training principles he promotes, and points listeners toward where they can explore his work online.Check out Jaquish Biomedical and their home gym here! https://www.tkqlhce.com/click-101633148-15734952Forum: https://www.facebook.com/groups/X3BarUsersGroupFollow Dr. Jaquish here:*YouTube:https://www.youtube.com/@JaquishBiomedical*Instagram: https://www.instagram.com/drjaquish/John Jaquish, PhD: After developing the worlds, most effective medical device for bone density generation, as well as a strength training system that's more effective for gaining muscle and strength than anything previous and used by some of the worlds greatest athletes (NBA, NFL, and Olympic). Dr. Jaquish developed a unique perspective on hormone optimization. His approach leaves patients with a biochemical demand for anabolic hormones, as opposed to the standard approach, which just introduces anabolic hormones, leaving the body confused as to what to do with them, thereby causing side effects. His WSJ best selling book describes this in detail, and is about to launch this new product for worldwide availability.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this session, Regan Archibald explores recent regulatory changes affecting peptides and what they could mean for clinicians, patients, and compounding pharmacies. He outlines how shifting FDA classifications may influence access to certain compounds while highlighting the broader tension between innovation, safety oversight, and pharmaceutical economics. The discussion also provides an overview of several commonly discussed peptides, explaining their origins as naturally occurring or derived molecules and their growing interest within personalized approaches to health. Throughout, Archibald emphasizes the importance of quality sourcing, regulatory awareness, and individualized strategies, framing the current moment as part of a larger transformation in how emerging therapies are evaluated, accessed, and integrated into modern healthcare.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss new data from a pre-specified expanded dataset analysis of the company's Phase 2 SKNJCT-003 clinical trial, highlighting a positive dose-response relationship for its Doxorubicin Microneedle Array in the treatment of nodular basal cell carcinoma, the most common form of skin cancer. Bokhari explained that the additional analysis builds on previously reported positive topline results, offering deeper biological, histologic, and safety insights that further strengthen the therapeutic profile of the company's SkinJect platform. He noted that the findings are consistent with earlier clinical data, including results from the Phase 1 SKNJCT-001 study conducted in 2021 and interim Phase 2 data reported in March 2025, reinforcing the reproducibility and reliability of the treatment approach across multiple studies. The SKNJCT-003 trial was designed as a randomized, double-blind, three-arm Phase 2 study evaluating two different dose levels of microneedle-delivered doxorubicin compared to a device-only control. Conducted across multiple clinical sites, the study enrolled approximately 90 patients diagnosed with nodular basal cell carcinoma, aiming to assess both safety and efficacy in a controlled setting. According to Bokhari, the expanded dataset—verified through centralized pathology review—provides a clearer and more clinically meaningful picture of treatment outcomes. Among the cohorts, the 200-microgram dose at Day 57 emerged as the most promising, demonstrating the strongest and most consistent efficacy signal. These results suggest that the treatment may offer a non-surgical alternative for certain patients, potentially reducing or delaying the need for immediate excision of cancerous lesions. Such an approach could represent a meaningful shift in the standard treatment paradigm for BCC, particularly given the relatively short treatment and evaluation window used in the study. Bokhari added that the data package could support future registration-focused discussions with the U.S. Food and Drug Administration (FDA), including considerations around optimal dosing, patient selection, lesion subtype, and treatment timelines. The company believes these findings position SkinJect as a potentially innovative and practical therapeutic option in the dermatologic oncology space. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #Oncology #MedicalInnovation #Healthcare #FDA #Biopharma
It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more. Announcing Community Commericals! Learn how to get your message on the show here. Don't miss our in-person events: www.diabetes-connections.com/events Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/ XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community. It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting?autologincheck=redirected XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. https://www.cbc.ca/news/health/ozempic-generic-health-canada-9.7180566 XX Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028. XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage. Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. https://www.msn.com/en-us/money/companies/insulet-recalling-certain-defective-omnipod-insulin-delivery-devices/ar-AA1YyslT?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company's Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it's the episode just before this one. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pumps-over-software-malfunction/818260/ XX Switching CGMs didn't make a measurable difference for adults using MiniMed's pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. "When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more," Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. "Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want." I'm including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. "More research is needed to see if there are other factors that are associated with risk reduction." https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world's first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study. The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can't necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison. The Virginia senator wrote on the social platform X, "As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we've received. Thank you to everyone for your kind words." Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were "heartbroken beyond words" by their daughter's passing. On Monday, the former Virginia governor said his daughter "was a deeply empathetic and engaged person" and that "as recently as the day she passed, she was full of ideas and suggestions" for him, including how he could improve his social media presence. "She used to say to me: 'Dad, you have the power — you have to use it.' She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways," he added. "If I can find any solace during this time, it's that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy's name." Warner concluded, "I look forward to returning to the Senate this week and continuing that essential work." Madison Warner is survived by two younger sisters. An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC's National Diabetes Statistics Report. An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes. Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D. The Halo Awards recognize the most outstanding corporate social impact efforts over the past year.
The American Food and Drug Administration (FDA) has just awarded fast track status to three companies developing psychedelic drugs as a treatment for addiction and other mental health issues. It comes after President Trump directed $50million dollars to increase their availability. Claudia Hammond is joined by BBC Brazil reporter Camilla Mota to discuss what claims are made for the effectiveness of these drugs.A novel house design, called “Star Homes”, which promote airflow, block insects, and feature rainwater collection systems, can reduce child mortality, demonstrated by a randomised controlled trial in Tanzania. We hear from Professor Lorenz Von Seidlein from the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok about what makes these homes effective in lowering rates of malaria, diarrhoea and acute respiratory infections.We hear that the Russian health minister has called for 1 in 3 Russians to be tested for HIV annually. Russia has long had high rates of HIV, but it now has the highest prevalence in Europe, with particularly high rates among Russian troops since the beginning of the Ukraine war.We also hear from David Méary, associate professor at the Université Grenoble Alpes, about whether infants have a sense of beauty. And Claudia and Camilla discuss habits that drive salt consumption in older people.Presenter: Claudia Hammond Producer: Hannah Robins and Jonathan Blackwell
In this conversation, Curtis Estes and Tamara Loehr share the vision behind BuCell, a peer-based forum designed to bring together leaders interested in exploring longevity, personal growth, and purpose. They discuss how the complexity of modern health information can feel overwhelming, and how structured, small-group forums create a safe space for open dialogue, shared experiences, and accountability. By combining expert insights, personal data, and community support, participants navigate their individual journeys while learning from one another. The discussion highlights the importance of connection, mindset, and taking a holistic approach to life, emphasizing that meaningful relationships and shared purpose are just as important as innovation and knowledge in shaping how people approach the second half of life.Tamara Loehr is a globally recognised impact investor and growth advisor, helping wellness and longevity companies unlock scalable, sustainable growth. With decades of experience building and scaling businesses, she partners with founders to drive both commercial performance and long-term impact. Known for her ability to align profit with purpose, Tamara has been named one of Forbes Top 11 Most Impactful Female Leaders and recognised in the Top 150 by Real Leaders.Guest Links: Website: Www.beusail.comLinkedIn: https://www.linkedin.com/in/curtisestes?utm_source=share_via&utm_content=profile&utm_medium=member_iosAgeless Future Resources:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this session, Regan Archibald explores the growing attention around GLP-1–related therapies, aiming to clarify common misconceptions while explaining how these compounds function in the body. He discusses their role in appetite regulation, metabolic processes, and behavioral patterns around food, while emphasizing that their effects can vary depending on dosage, combination with other compounds, and individual use patterns. The conversation highlights both the enthusiasm and concerns surrounding their widespread adoption, including cultural trends, evolving research, and unintended consequences when overused. Throughout, Archibald advocates for a more measured, individualized approach that integrates broader lifestyle considerations such as nutrition, environment, and long-term habits rather than relying on any single intervention.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this episode, the speaker reframes longevity as an ongoing skill set shaped by consistent daily behaviors rather than one-time solutions. The discussion emphasizes a proactive, data-informed approach to health, encouraging individuals to track patterns such as energy, recovery, sleep, and nutrition to better understand how their bodies respond over time. Rather than focusing on perfection or quick fixes, the conversation highlights the value of gradual improvement, adaptability, and long-term habit formation. Key themes include the role of lifestyle foundations like movement, nutrition, sleep, and stress management, as well as the use of tools such as wearables and lab testing to monitor trends. Overall, the episode promotes a systems-based perspective on well-being, where small, consistent actions compound to support performance and quality of life over time.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Government Accountability Office (GAO) Podcast: Watchdog Report
New tobacco product must first be approved by the Food and Drug Administration (FDA) before being sold in the United States. Despite this requirement, there are thousands of unapproved e-cigarette products and devices being sold. We learn about this…
In this episode, Cade Archibald explores the concept of “inflammaging,” described as a persistent, low-grade immune activation that can quietly influence how the body functions over time. The discussion highlights how everyday factors—such as stress, sleep patterns, diet, and environmental exposures—may contribute to this ongoing internal “noise,” even when no obvious symptoms are present. Emphasis is placed on the importance of balancing periods of stress with recovery, as well as adopting supportive lifestyle habits like regular movement, consistent sleep, and mindful routines. The episode frames aging not just as a matter of time, but as a reflection of how well the body maintains equilibrium amid modern demands.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events shaping the industry, from groundbreaking drug approvals to strategic corporate maneuvers.Recently, the U.S. Food and Drug Administration (FDA) granted approval for Eli Lilly's new GLP-1 receptor agonist pill, Foundayoby, marking a significant milestone as it's the first new molecular entity to be cleared under the FDA's Commissioners National Priority Voucher Program. This program is designed to expedite the review process for drugs addressing critical needs or representing substantial advancements in treatment. Foundayoby's entry into the market provides a competitive edge against Novo Nordisk's products, offering a convenient oral alternative in the management of type 2 diabetes and obesity. Clinical trials have shown that this oral formulation maintains efficacy comparable to injectable peptides while improving patient adherence due to its ease of use. This development not only broadens therapeutic options but also emphasizes the growing trend towards patient-centric formulations in diabetes management.In related news, Eli Lilly has also received FDA approval for its oral obesity medication, Orforglipron, marketed as Foundayo. This approval further intensifies the rivalry with Novo Nordisk, which launched its oral therapy Wegovy earlier. Orforglipron's clinical trials demonstrated significant weight reduction in patients, highlighting pharmacotherapy's rising importance as an option for individuals struggling with obesity despite lifestyle modifications. The convenience of an oral formulation is expected to enhance patient compliance and long-term success, addressing a key challenge in obesity management.In strategic corporate news, Korsana Biosciences is making waves by entering public markets through a reverse merger with Cyclerion. This move highlights ongoing interest and investment in neurodegenerative diseases like Alzheimer's. In contrast, KBP Biosciences faces legal challenges as it seeks to reclaim ownership of heart drug Ocedurenone from Novo Nordisk after a failed billion-dollar deal. Such cases underscore the complexities inherent in pharmaceutical collaborations.Regulatory scrutiny continues to play a crucial role in shaping industry dynamics. The FDA extended its review period for Orca Bio's novel cell therapy for blood cancers by three months. This delay reflects rigorous regulatory requirements for innovative treatments poised to transform oncology care paradigms. Meanwhile, Iterum Therapeutics is winding down operations following unsuccessful sales of its antibiotic Orlynvah, highlighting financial sustainability challenges within the antibiotic market.Safety remains paramount as evidenced by concerns over Amgen's Tavneos after reports of serious liver injuries linked to its use. The FDA has identified 76 cases, including fatalities, underscoring the importance of post-market surveillance and risk management in ensuring patient safety.In terms of mergers and acquisitions, Eli Lilly's strategic acquisition of Centessa Pharmaceuticals for $6.3 billion signifies its entry into the sleep disorder market. Biogen followed suit by acquiring Apellis Pharmaceuticals for $5.6 billion to strengthen its kidney disease expertise. These moves reflect a broader trend where pharmaceutical giants are diversifying portfolios through acquisitions targeting niche therapeutic areas.On the technological front, partnerships leveraging artificial intelligence (AI) are gaining traction. Bristol Myers Squibb's collaboration with Faro Technologies aims to refine clinical trials using AI, while Merck & Co.'s partnership with Infinimmune focuses on antibody discovery innovations.Financially, Blackstone's record-breaking $6.3 billion life sciences fund highlights robust invSupport the show
In this Ageless Future podcast episode, Cade Archibald continues a prior discussion on the nervous system by focusing on practical, non-clinical ways to support balance and resilience. He emphasizes that daily habits such as consistent sleep, whole-food nutrition, hydration, movement, stress awareness, social connection, and evening routines create the foundation for feeling and functioning better, while supplements and peptides are framed as supportive tools rather than shortcuts. Throughout the conversation, he encourages listeners to pay attention to how stress, environment, and routines affect their overall well-being, and to build simple, sustainable practices that promote steadier energy, better focus, and a more regulated day-to-day experience.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Dr. Tommy Wood discusses evidence that stimulants can help people with ADHD but may worsen complex cognitive performance in non-ADHD users despite feeling more focused. He outlines an ideal brain-health day centered on consistent sleep opportunity, morning caffeine timed to protect sleep, nutrient-dense meals (protein, B vitamins, omega-3s, fiber, antioxidants), frequent movement to break up sedentary time, and structured exercise including cardio, resistance training, HIIT (notably Norwegian 4x4), and open-skill sports for added cognitive benefits. He emphasizes bright morning light and darkness at night for circadian strength, notes optic-flow/nature exposure as helpful but not required, and says electrolytes/salt needs are individual. The conversation covers cognitive decline and bioenergetics/mitochondria, critiques "type 3 diabetes" as oversimplified, reviews mixed evidence for ketones, and addresses supplements (omega-3s, vitamin D, saffron, creatine, polyphenols). Screens can help or harm depending on use and what they displace. Wood promotes his book, "The Stimulated Mind," out March 24. Dr. Tommy Wood is a physician-scientist and brain health expert who helps people better understand how to improve cognition, protect memory, and reduce long-term dementia risk. With a focus on exercise, sleep, nutrition, and brain energetics, he explores the practical habits that support focus, processing speed, recovery, and healthy cognitive aging. Dr. Wood is known for translating complex neuroscience into clear, actionable advice, while challenging oversimplified ideas around stimulants, supplements, and modern brain optimization. Through his research, speaking, and new book The Stimulated Mind, Dr. Wood teaches people how to create the right conditions for better brain function across the lifespan. His work empowers listeners to think of brain health as something trainable—shaped by movement, sleep, learning, and the quality of the inputs we give our minds every day. Books & Main Episode Resources The Stimulated Mind Official book page: https://www.drtommywood.com/stimulated-mind Publisher page: https://www.penguinrandomhouse.com/books/751292/the-stimulated-mind-by-dr-tommy-wood/ Dr. Tommy Wood Official website: https://www.drtommywood.com/ Instagram: https://www.instagram.com/drtommywood/ Podcasts, People & Platforms The Diary of a CEO Official show page: https://stevenbartlett.com/doac/ Joe Rogan Experience Official site: https://www.joerogan.com/ Spotify show page: https://open.spotify.com/show/4rOoJ6Egrf8K2IrywzwOMk Dr. Rhonda Patrick / FoundMyFitness Official site: https://www.foundmyfitness.com/ About Dr. Rhonda Patrick: https://www.foundmyfitness.com/about-dr-rhonda-patrick Medications & Prescription Drugs Mentioned Provigil (modafinil) DailyMed label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8 Vyvanse (lisdexamfetamine) DailyMed label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad Concerta (methylphenidate) Official prescribing info: https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/CONCERTA-pi.pdf Adderall DailyMed label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81 Adderall XR DailyMed label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0 Aricept (donepezil) FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020690s042,021720s014,022568s011lbl.pdf Hydration / Electrolytes LMNT Official site: https://drinklmnt.com/ Research, Labs & Studies Mentioned COSMOS Trial Official site: https://cosmostrial.org/ ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03035201 Institute for Human and Machine Cognition (IHMC) Official site: https://www.ihmc.us/ Jonathan Little Lab (UBC) Faculty page: https://hes.ok.ubc.ca/about/contact/jonathan-little/ Lab site: https://emil.ok.ubc.ca/ Show Notes 00:00 Stimulants Backfire 00:56 Plan Sleep First 02:33 Caffeine Timing 04:24 Brain Food Basics 05:12 Move All Day 06:00 Workouts That Help 07:26 Social Connection Matters 08:36 Sunlight Optic Flow Hydration 13:31 Exercise Types Compared 16:02 HIIT Lactate Brain Boost 18:18 Open Skill Sports 21:45 ADHD Meds Long Term 26:51 Which Med Is Best 27:59 Cognitive Decline Energy 28:27 Brain Energy Risk Factors 29:04 Stimulus Drives Brain Health 30:57 Type Three Diabetes Debate 33:42 Ketones and Cognition 37:13 Mitochondria and Decline 38:42 Omega Three Practical Dosing 41:45 Vitamin D and Dementia Risk 43:13 Saffron Hype Check 45:03 Creatine for the Brain 50:28 Polyphenols Diet vs Pills 52:41 Screens AI and Brain Use 55:31 Book Plug and Wrap Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode of the Ageless Future podcast, Cade Archibald discusses how the nervous system continuously responds to signals of stress and safety, and how those patterns can shape energy, sleep, digestion, and recovery. He explores the difference between short-term activation and prolonged stress, emphasizing the importance of creating boundaries between periods of effort and periods of rest. The conversation also highlights practical lifestyle themes such as sleep routines, exercise balance, time away from constant alerts, and daily habits that may support resilience and recovery, with the overall message centered on the value of regulating stress rather than trying to eliminate it entirely.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this session, Regan Archibald introduces the idea of “metabolic flexibility” as the body's ability to use different fuel sources efficiently and connects that concept to daily habits, energy, and lifestyle choices. He frames the discussion around practical routines such as regular movement, strength training, walking after meals, prioritizing sleep, eating balanced meals with enough protein and fiber, and paying attention to how food choices affect overall wellbeing. He also discusses the role of muscle, activity, and consistency in supporting long-term health habits, while encouraging listeners to observe their own patterns through tools like blood work or a continuous glucose monitor and to focus on sustainable behaviors rather than relying on willpower alone.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this episode of the Ageless Future podcast, Regan Archibald talks with Dr. Peter Martone about his approach to improving sleep by focusing on bedtime setup, body positioning, and consistent pre-sleep routines. Drawing on his background in biomechanics and his own experience with injury, Martone explains why he believes posture, comfort, and nervous system calming all play a role in how well people rest. He describes a framework that includes tracking sleep-related metrics, using breathing and scent-based routines to create relaxation cues, and identifying different “sleep avatars” to personalize bedtime habits. Throughout the conversation, he encourages listeners to think of better sleep as something supported by intentional routines and environment, rather than just chasing sleep products or quick fixes.Dr. Peter Martone is a chiropractor, exercise physiologist, and injury prevention specialist with over 25 years of experience helping patients improve their biomechanics and overall health. He focuses on the connection between spinal alignment and nervous system function, using this principle to help people achieve deeper, more restorative sleep. After noticing the impact of modern lifestyles on posture, he developed innovative techniques to correct spinal alignment during sleep. His work has been featured on major media outlets like CBS, NBC, and Fox News, and he travels internationally teaching his approach to better health through better sleep.LIKE/FOLLOW/SUBSCRIBE DR. SLEEP RIGHT:Drsleepright.com Instagram: https://www.instagram.com/drsleepright/ Facebook: https://www.facebook.com/DoctorSleepRight/ YouTube: https://www.youtube.com/channel/UCqkL_8cF7nvdNzT-Z6E8gzgAGELESS FUTURE RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Regan Archibald sits down with Eric Edmeades (creator of WildFit) to explore the idea of “evolutionary mismatch”—how modern environments, routines, and food systems can pull people away from the conditions humans historically adapted to. Eric shares stories from multiple immersive visits with the Hadzabe in Africa, including lessons about food priorities, movement, and seasonal eating, and contrasts those patterns with rapid shifts he's observed in places like the UK, Estonia, and Dubai as ultra-processed foods and convenience culture spread. The conversation also touches on behavior change, the role of mood and environment in food choices, and Eric's “Gap Finder” assessment—an evaluation designed to help people identify everyday lifestyle “gaps” and choose practical next steps, combining ancestral insights with modern tools and coaching programs.ERIC:Website: https://ericedmeades.com/Instagram: https://www.instagram.com/ericedmeades/Facebook: https://www.facebook.com/ericedmeadesYouTube: https://www.youtube.com/@AWilderLifewithEricEdmeadesRESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this episode of the Health Accelerator Challenge, Regan Archibald discusses the concept of VO₂ max and why it is widely studied as a measure of cardiorespiratory fitness. He explains what VO₂ max represents—how the body transports and uses oxygen during intense activity—and why it is often used as a benchmark for physical conditioning. Drawing on research, personal training experiences, and stories from clients, he shares how structured exercise approaches like interval training and zone-based cardio can influence performance metrics over time. The conversation also touches on tools for measuring fitness, the role of accountability and goal-setting, and emerging areas of interest in mitochondrial and regenerative health, while emphasizing that consistent exercise remains a foundational part of maintaining physical capacity and enjoying an active lifestyle.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
The script explains why fiber is critical for gut and metabolic health, focusing on how soluble fiber is fermented in the colon to produce short-chain fatty acids (butyrate, propionate, acetate). It contrasts soluble fiber (forms a gel, lowers LDL by binding bile acids, slows glucose absorption, increases satiety, feeds the microbiome) with insoluble fiber (adds stool bulk, helps constipation). It highlights research showing 10 g/day psyllium husk (Metamucil) is linked to a 10% reduction in all-cause mortality and typically lowers LDL about 7–15%. Butyrate is emphasized as the primary fuel for colonocytes, supporting gut barrier integrity and potentially reducing colon cancer risk, while also affecting mitochondria, inflammation, and the brain. Propionate influences liver cholesterol production and satiety hormones, and acetate provides systemic energy. Practical supplementation "stacks," dosing ranges, food sources, GI side effects, and timing cautions (e.g., separating psyllium from minerals) are discussed. Metamucil (psyllium husk fiber) — https://www.metamucil.com/ Psyllium husk (soluble fiber) — https://medlineplus.gov/druginfo/meds/a601104.html Psyllium husk (PubMed search) — https://pubmed.ncbi.nlm.nih.gov/?term=psyllium+husk Soluble fiber (overview) — https://medlineplus.gov/dietaryfiber.html Insoluble fiber (overview) — https://medlineplus.gov/dietaryfiber.html Inulin (prebiotic fiber) — https://pubmed.ncbi.nlm.nih.gov/?term=inulin+prebiotic+fiber Acacia fiber / Gum arabic (prebiotic fiber) — https://pubmed.ncbi.nlm.nih.gov/?term=acacia+fiber+gum+arabic+prebiotic Beta-glucan (oats/barley soluble fiber) — https://pubmed.ncbi.nlm.nih.gov/?term=beta-glucan+oats+LDL Pectin (soluble fiber) — https://pubmed.ncbi.nlm.nih.gov/?term=pectin+soluble+fiber Partially hydrolyzed guar gum (PHGG) — https://pubmed.ncbi.nlm.nih.gov/?term=partially+hydrolyzed+guar+gum Resistant starch / Potato starch — https://pubmed.ncbi.nlm.nih.gov/?term=resistant+starch+potato+starch Short-chain fatty acids (SCFAs) — https://www.ncbi.nlm.nih.gov/books/NBK557571/ Butyrate (SCFA) — https://pubmed.ncbi.nlm.nih.gov/?term=butyrate+short-chain+fatty+acid+colonocytes LDL cholesterol (general) — https://medlineplus.gov/cholesterol.html Magnesium (mineral supplement info) — https://medlineplus.gov/magnesium.html Show Notes 00:00 Butyrate and Colon Health 00:49 Why Fiber Matters Now 02:28 How Fiber Is Digested 03:45 Soluble vs Insoluble Fiber 06:36 Gel Effect on Blood Sugar 07:36 How Soluble Fiber Lowers LDL 10:19 Short Chain Fatty Acids 101 11:32 Butyrate Deep Dive 16:40 Propionate and Liver Benefits 18:22 Acetate for Energy and Appetite 19:29 Best Fibers to Supplement 21:33 Dosing and Food Sources 24:44 Ideal Fiber Stack and Safety 28:37 Wrap Up and Next Steps The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode of Creating Your Ageless Future (Health Accelerator Challenge), Regan Archibald uses a “peptides as information” framework to discuss how peptides fit into the broader landscape of modern health and wellness. He contrasts how pharmaceuticals are typically defined and evaluated (including the clinical trial pathway) with the way he thinks about peptides as signaling molecules that interact with receptors and influence cellular communication. Along the way, he shares analogies (like texting vs. phone calls) to explain why context—such as lifestyle factors and individual variability—matters when people talk about outcomes, and he cautions against DIY protocols and unreliable sourcing. He closes by encouraging education, responsible oversight, and participation in upcoming community events.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia
In this episode of the Ageless Future podcast, host Cade Archibald sits down with Dr. Brandon Burke to explore his journey from building multiple successful orthodontic practices to stepping into a new chapter focused on coaching and personal development. Brandon shares how growing up in a small Utah town shaped his drive, what it looked like to build a practice from scratch during the recession, and the moment he realized his achievements weren't the same as fulfillment. The conversation dives into themes of identity, burnout, resilience, and “unbecoming”—letting go of external validation to reconnect with purpose, emotional awareness, and grounded leadership in family and community. Brandon closes with a message about choosing to live as a creator rather than a victim, and how his most difficult season became the turning point that helped him realign his life.BRANDON BURKE:Websites: gettinlostisbeingfound.com and more-than-love.comIG: https://www.instagram.com/gettinlostisbeingfound/FB: @safetobeseenTikTok: https://www.tiktok.com/@gettinlostisbeing/YouTube: Safe To Be Seen~ https://youtube.com/@safetobeseenPodcast: https://podcasts.apple.com/us/podcast/safe-to-be-seen/id1817823527AGELESS FUTURE:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Dr. Roger McFillin argues that Western allopathic medicine and psychiatry have medicalized normal human suffering by reducing emotions to biological or chemical reactions, turning symptom checklists into fixed identities, and sustaining a drug-driven "sick care" system that creates lifelong customers. He contrasts this with viewing emotions as powerful energy meant to be moved into creation and transformation, cites psychoneuroimmunology, and warns that suppressing fear and distress with pharmaceuticals can worsen long-term outcomes. The conversation covers exposure-based approaches to unlearn fear, the role of media, social media, and advertising in provoking fear and keeping people in an unconscious "drift" state, and the importance of intentional stillness, solitude (distinct from loneliness), prayer or silent meditation, and reducing phone use—especially at the start of the day—to become more conscious and intentional. McFillin discusses how diagnostic labels like depression and anxiety shape identity, limit choices, and contribute to chronicity and polypharmacy. He contrasts PTSD with post-traumatic growth, emphasizing processing trauma memories, facing avoided situations, challenging overgeneralized threat beliefs, and practicing forgiveness and self-compassion while also taking ownership where appropriate. They also discuss the perceived harms of the "toxic masculinity" concept, men's wellbeing, the loss of wise elders, and how men often bond and cope through shared activities. Dr. Roger McFillin is a clinical psychologist and trauma recovery expert who challenges the medicalization of normal human emotions. With a focus on emotional resilience and personal growth, he specializes in exposure therapy and psychoneuroimmunology, exploring the connection between mind, emotions, and immune health. Dr. McFillin advocates for self-regulation and transforming emotional energy into healing, critiquing the overuse of pharmaceuticals in modern mental health treatment. Through his Substack, Radically Genuine, and podcast, Dr. McFillin educates individuals on overcoming fear, achieving stillness, and reconnecting with their true selves. His work empowers people to shift from a victim mindset to one of active growth, using trauma as a catalyst for resilience and positive change. Science & Medicine Psychoneuroimmunology Overview & science (NIH): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130991/ Exposure Therapy Wikipedia overview: https://en.wikipedia.org/wiki/Exposure_therapy Cleveland Clinic explanation: https://my.clevelandclinic.org/health/treatments/25067-exposure-therapy Anxiety & OCD exposure-based approaches (IOCDF): https://iocdf.org/about-ocd/treatment/erp/ Heart Coherence HeartMath Institute overview: https://www.heartmath.org/heart-coherence/ Psychiatric Diagnosis & DSM Critique of DSM and diagnostic categories: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195174/ Psychiatric diagnosis controversies: https://www.apa.org/monitor/2013/04/diagnosis Psychology & Healing Post-Traumatic Growth vs. PTSD Scientific overview of post-traumatic growth: https://www.apa.org/monitor/2014/01/psychological-recovery Journal article on PTG vs PTSD: https://www.sciencedirect.com/science/article/abs/pii/S0272735814000412 Forgiveness and Healing Psychology Today on forgiveness: https://www.psychologytoday.com/us/basics/forgiveness Research evidence on forgiveness and wellbeing: https://journals.sagepub.com/doi/10.1177/1745691614568356 Self‑Healing Practices Grounding / Earthing What is grounding/earthing? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378297/ PEMF (Pulsed Electromagnetic Field) Therapy Basics of PEMF therapy: https://www.health.harvard.edu/pain/pulsed-electromagnetic-field-therapy Meditation & Stillness Mindfulness & stillness research: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422583/ Psychology Today on solitude and healing: https://www.psychologytoday.com/us/blog/hide-and-seek/201209/finding-solitude-its-benefits-and-challenges Cultural & Media Influence Mind Control & Fear Provocation The psychology of fear in media messaging: https://www.frontiersin.org/articles/10.3389/fpsyg.2020.566245/full Media influence and persuasion research: https://www.communicationtheory.org/agenda-setting-theory/ Toxic Masculinity Research overview on toxic masculinity: https://www.apa.org/advocacy/health-men/guidelines What toxic masculinity means: https://www.psychologytoday.com/us/blog/the-masculine-mind/201802/what-toxic-masculinity Dr. Roger McFillin Content Substack (Radically Genuine): https://drmcmillan.substack.com Show Notes 00:00 Emotions as Energy 00:33 Medicalizing Suffering 02:44 Exposure Beats Suppression 05:18 Fear and Mind Control 10:21 Stillness vs Loneliness 14:47 Simple Stillness Practices 20:12 Morning Intention Rituals 25:56 Labels and Identity Traps 31:26 Systemic Treatment Harm 32:53 Depression Label Identity 35:08 Sadness Versus Pathology 36:10 PTSD And Growth 38:24 Processing Trauma Fully 41:44 Practical Recovery Steps 45:48 Forgiveness And Ownership 50:37 Toxic Masculinity Debate 56:12 Men Friendship And Elders 01:01:05 Closing Plugs Farewell 38:24 How PTSD Develops 41:44 Practical Trauma Recovery 45:48 Forgiveness and Ownership 50:37 Toxic Masculinity Debate 56:12 Male Friendship and Elders 01:01:05 Closing and Where to Follow The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode of Creating Your Ageless Future, Regan Archibald offers a high-level, educational walkthrough of regenerative medicine—covering commonly discussed categories like biologics, cellular therapies, signaling molecules, PRP, and exosomes—while emphasizing the importance of separating marketing from evidence. He shares why public interest has accelerated (including demographic and cultural factors), describes how product variability and regulatory action have shaped the landscape, and explains why research concepts like cell sourcing, handling, and testing are central to quality and safety discussions. Regan also outlines how teams often approach decision-making in this space—using diagnostics, careful sourcing, and lifestyle context—while cautioning against one-size-fits-all claims and DIY experimentation.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around those patients who have high immune risks. Those include patients with autoimmune disorders. That's one of our biggest questions that we ask, usually every consult that we're seeing with solid tumor. 'Do you have any history of autoimmune disorders? Tell me a little bit more about it. Is it being treated? What are your symptoms like?' And then also patients who have undergone organ transplants. Now, interestingly, this does include stem cell transplants," Kelsey Finch, PharmD, BCOP, oncology pharmacist practitioner at Columbus Regional Health in Indiana, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about checkpoint inhibitors. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 20, 2027. Kelsey Finch has disclosed a speakers bureau relationship with AstraZeneca. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to checkpoint inhibitors in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 273: Updates in Chemotherapy and Immunotherapy Episode 174: Administer Pembrolizumab Immunotherapy With Confidence Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment ONS Voice articles: Here's Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events Make Subcutaneous Administration More Comfortable for Your Patients Nursing Considerations for ICI-Related Myocarditis Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology Postdischarge ICI Patient Education Eliminates Hospital Readmissions Shorter Administration Times Still Require High-Acuity Care ONS Voice oncology drug reference sheets: Dostarlimab-Gxly Nivolumab and Hyaluronidase-Nvhy Nivolumab and Relatlimab-Rmbw Pembrolizumab and Berahyaluronidase Alfa-Pmph Retifanlimab-Dlwr Toripalimab-Tpzi ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing articles: Immune Checkpoint Inhibitor–Related Myocarditis: Recognition, Surveillance, and Management Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers ONS Huddle Cards: Checkpoint Inhibitors Immunotherapy ONS Learning Libraries: Genomics and Precision Oncology Learning Library Immuno-Oncology Learning Library Drugs@FDA package inserts National Comprehensive Cancer Network homepage OncoLink: All About Immunotherapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Before immune checkpoint blockade, the two-year overall survival rate in metastatic melanoma was hovering around 10%. After these agents came to market, depending on the trial and the agents used, that number actually increased to about 50%–65%. So, five times the amount of patients were actually living at the two-year mark. Not surprisingly, studies then exploded across several tumor types, leading to approvals in all sorts of cancers, mostly in the solid tumor. But there are a couple hematologic as well. Lung cancer, kidney cancer, head and neck, Hodgkin lymphoma, hepatocellular, the list goes on. So, it's really just transforming the stage IV setting across all tumors, specifically from uniformly fatal prognosis to one where durable responses and long-term survival is also possible." TS 3:03 "There are four different mechanisms officially being used in therapies that are approved by the U.S. Food and Drug Administration (FDA). Those are cytotoxic T-lymphocyte–associated protein 4, programmed cell death protein 1, and programmed cell death ligand 1, which I'm counting as two different mechanisms, even though they somewhat work together. And lymphocyte-activation gene 3 is the fourth one that's in there. So, all these mechanisms impact the T cell in our immune system. The T cell is traditionally responsible for protecting our body from harmful things like bacteria, viruses, and cancer. When the tumor binds to cytotoxic T-lymphocyte–associated protein 4 receptors, that happens on the T cell itself. And that inhibits the activation of the T cells, essentially allowing that tumor to then live. So when developing medications that block this receptor, they noted an added benefit that it actually increased the T-cell proliferation as well as keeping that T cell active. So not only are we not blocking the T cells, we're making them more productive." TS 5:38 "If you have a chance of any sort of tissue rejection, specifically with allogeneic stem cell transplants or where we see that focusing on it, there's a little bit of controversy, mixed bag on opinions as far as autologous stem cell transplants. But it's best to at least exercise a little bit of caution. If they have a chance of organ rejection, is that worth the risk of the therapy that we're looking to give? And then, patients with HIV, any sort of immunologic concerns at baseline that we could potentially worsen." TS 14:37 "As a rule of thumb, with immune checkpoint blockade, regardless of what mechanism you're looking at, if something in your body can get inflamed, that can wind up as an adverse event. So, whenever I talk to my patients, the key word is anything ending in '-itis.' ... The most common adverse events that we end up seeing are dermatitis and hypothyroidism. Immune checkpoint blockade can cause both hyper- and hypothyroidism. Very often, we actually start in the hyper- and then end up, for lack of better words, burning out the thyroid, ultimately leading to a sustained hypothyroidism." TS 18:34 "The half-life of immune checkpoint inhibitors is usually around 30 days, meaning that once these agents are given, the drug will be in the patient's system for up to five months. Specifically, it will probably build month to month, so often we don't even see a lot of our adverse events until month three or four. Usually, when we're that far into treatment, we're not looking for new adverse events in things like chemotherapy. But these drugs do build over time." TS 24:28 "As far as safe handling is concerned, these agents are not chemotherapy. That makes drug compounding and administration pretty straightforward. When looking at the follow-up care, the most important thing, in my opinion, is to engage in meaningful dialogue with your patients. A lot of the side effects can be nonspecific. So, really listening to the patient and evaluating changes in their lifestyle, I think it'll get you far. We usually hark in on the new, worsening, or persistent whenever we're talking to patients because they'll be looking for things as well. So, just having a dialogue of how their life has changed can certainly help." TS 26:17
This episode explores tadalafil (Cialis) as a potential longevity drug, though no randomized human trials prove it extends lifespan. Cialis works by blocking PDE5, enhancing nitric oxide signaling, and improving blood flow through vasodilation. Originally approved for pulmonary hypertension, it's also used for erectile dysfunction and BPH. Its 36-hour half-life makes it superior to Viagra for continuous longevity effects. The host frames vascular aging and endothelial dysfunction as key drivers of age-related diseases (heart disease, stroke, dementia, kidney disease). Observational data shows Cialis users have 44% lower mortality, fewer cardiovascular events, reduced dementia risk, and lower mortality in diabetics. Additional benefits include improved cardiac function, reduced infarct size, arrhythmia suppression, and regression of left ventricular hypertrophy. A 2024 meta-analysis found it lowers hemoglobin A1C, possibly via improved microvascular perfusion, insulin sensitivity, and mitochondrial function. Cialis crosses the blood-brain barrier and may improve neurovascular coupling and hippocampal plasticity, potentially benefiting those with or at risk of dementia. Safety is generally good with long-term daily use (2.5–5 mg), though cautions include avoiding use with nitrates, low blood pressure, or certain retinal disorders. Common side effects are headache, nasal congestion, and acid reflux. The host recommends consulting a doctor and references potential synergy with telmisartan. Tadalafil (Cialis) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a604008.html](https://medlineplus.gov/druginfo/meds/a604008.html) Sildenafil (Viagra) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a699015.html](https://medlineplus.gov/druginfo/meds/a699015.html) Key mechanisms mentioned Nitric Oxide (NO) — NCBI Bookshelf: [https://www.ncbi.nlm.nih.gov/books/NBK554485/](https://www.ncbi.nlm.nih.gov/books/NBK554485/) Cyclic GMP (cGMP) — NCBI Bookshelf: [https://www.ncbi.nlm.nih.gov/books/NBK542234/](https://www.ncbi.nlm.nih.gov/books/NBK542234/) Conditions mentioned in the episode Benign Prostatic Hyperplasia (BPH) — MedlinePlus: [https://medlineplus.gov/benignprostatichyperplasia.html](https://medlineplus.gov/benignprostatichyperplasia.html) Pulmonary Arterial Hypertension (PAH) — MedlinePlus: [https://medlineplus.gov/pulmonaryhypertension.html](https://medlineplus.gov/pulmonaryhypertension.html) Blood pressure drug mentioned Telmisartan — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a601249.html](https://medlineplus.gov/druginfo/meds/a601249.html) Other longevity / comparison drugs mentioned Metformin — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a696005.html](https://medlineplus.gov/druginfo/meds/a696005.html) Sirolimus (Rapamycin) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a602026.html](https://medlineplus.gov/druginfo/meds/a602026.html) Side-effect helper mentioned Ibuprofen (Advil) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a682159.html](https://medlineplus.gov/druginfo/meds/a682159.html) Dementia meds mentioned Donepezil (Aricept) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a697032.html](https://medlineplus.gov/druginfo/meds/a697032.html) Amantadine — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a682064.html](https://medlineplus.gov/druginfo/meds/a682064.html) Lab markers mentioned Hemoglobin A1C (HbA1c) test — MedlinePlus lab test: [https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/](https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/) Insulin in blood test — MedlinePlus lab test: [https://medlineplus.gov/lab-tests/insulin-in-blood/](https://medlineplus.gov/lab-tests/insulin-in-blood/) People referenced (where the claims were mentioned) Huberman Lab (Dr. Andrew Huberman) — site: [https://www.hubermanlab.com/](https://www.hubermanlab.com/) Clip about low-dose tadalafil (2.5–5mg) — X post: [https://x.com/tbpn/status/2022350426394534334](https://x.com/tbpn/status/2022350426394534334) Bryan Johnson (Blueprint) — site: [https://blueprint.bryanjohnson.com/](https://blueprint.bryanjohnson.com/) Dr. David Sinclair (Harvard profile) — site: [https://sinclair.hms.harvard.edu/people/david-sinclair](https://sinclair.hms.harvard.edu/people/david-sinclair) Show Notes 00:00 Welcome to the Hart2Heart Podcast. 01:56 What Cialis Is: PDE5 Inhibition, cGMP & Nitric Oxide Explained 03:43 Approved Uses & Origin Story: Pulmonary Hypertension, ED, and BPH 05:33 Why Cialis Over Viagra: 36-Hour Half-Life & 24/7 Vascular Benefits 06:52 Vascular Aging 101: Endothelium, Perfusion, and Why It Drives Disease 11:14 What the Human Data Shows: Observational Evidence for Mortality, CVD & Dementia 13:04 Mechanisms Deep Dive: Heart Protection, Heart Failure, and Anti-Atherosclerosis 15:02 Cialis for Diabetics: Lowering A1C and Improving Insulin Sensitivity 16:21 Brain Effects: Blood–Brain Barrier, Neurovascular Coupling & Dementia Potential 18:21 Safety, Who Should Avoid It, and Daily Longevity Dosing (2.5–5 mg) + Wrap-Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Regan Archibald welcomes the audience and shares updates from recent travel before outlining how his “Ageless Future operating system” uses lab data to guide a more intentional health strategy. He emphasizes starting with clarity about goals and symptoms, then looking for patterns and trends across markers rather than relying only on standard reference ranges or single numbers. He discusses examples of deeper testing beyond common basics, the value of tracking data over time, and the importance of viewing markers in context—such as sleep, stress, nutrition, and training—so decisions are based on a fuller picture. He also highlights how inflammation and hormone-related markers can be considered as part of an integrated review, and closes by encouraging viewers to stay current with labs and contact the office or website to get testing scheduled if it's been more than six months.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Dinesh Patel, PhD, CEO of Protagonist Therapeutics, discusses the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV).PV is characterized by excess red blood cells in the bloodstream, increasing the risk for blood clots. Most cases of PV are acquired and occur more frequently in men than in women. The condition has been associated with genetic changes in the JAK2 and TET2 genes. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV.The NDA submission is based on positive 32-week primary analysis and 52-week results from the phase 3, global, randomized, placebo-controlled VERIFY clinical trial (NCT05210790). In this study, patients receiving rusfertide plus standard of care therapy demonstrated a substantially higher response rate compared to placebo plus standard of care, including durable hematocrit control, a reduction in phlebotomy requirements and improvement in pre-specified patient reported outcome endpoints.Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show
In this podcast episode, an in-depth discussion is provided on the drug Telmisartan, commonly used for lowering blood pressure. The host elaborates on how it belongs to a class of medications known as angiotensin receptor blockers (ARBs) and stands out due to its 24-hour half-life and partial PPAR-gamma agonist activity. The episode explores Telmisartan's potential benefits for longevity, including its properties that reduce cardiovascular mortality, renal decline, and metabolic issues. It also compares Telmisartan with other ARBs and addresses its unique ability to improve myocardial efficiency, reduce arterial stiffness, and support neuroprotection. Detailed explanations are given on technical concepts such as pulse pressure and its relevance to arterial compliance, and the necessity to consult a doctor before taking the medication is emphasized. Telmisartan / ARBs (main topic) Telmisartan — MedlinePlus drug info: https://medlineplus.gov/druginfo/meds/a601249.html Blood pressure meds overview (includes ARBs): https://medlineplus.gov/bloodpressuremedicines.html Key mechanisms mentioned PPARγ (PPARG) — NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/5468 Endothelium + nitric oxide (NO) — NCBI Bookshelf: https://www.ncbi.nlm.nih.gov/books/NBK534266/ Angiotensin / aldosterone / "fight-or-flight" Aldosterone test — MedlinePlus lab test: https://medlineplus.gov/lab-tests/aldosterone-test/ Sympathetic nervous system ("fight-or-flight") — Cleveland Clinic explainer: https://my.clevelandclinic.org/health/body/23262-sympathetic-nervous-system-sns-fight-or-flight Lab tests mentioned in the episode Fasting insulin ("Insulin in Blood") — MedlinePlus lab test: https://medlineplus.gov/lab-tests/insulin-in-blood/ Hemoglobin A1C (HbA1c) — MedlinePlus lab test: https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/ C-reactive protein (CRP) — MedlinePlus lab test: https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/ Arterial stiffness / pulse pressure (longevity framing) Pulse pressure & arterial stiffness as risk predictors — PubMed: https://pubmed.ncbi.nlm.nih.gov/11224702/ Visceral fat resource mentioned Dr. Sean O'Mara website: https://drseanomara.com/ Show Notes 00:00 Welcome to the Hart2Heart Podcast. 01:22 Understanding Angiotensin and Its Effects 02:14 How ARBs Work and Their Benefits 03:00 Unique Properties of Telmisartan 03:36 Comparing Telmisartan with Other ARBs 04:44 Telmisartan's Impact on Endurance and Fat Loss 05:59 Telmisartan and Cardiovascular Health 09:57 Blood Pressure Basics and Pulse Pressure 18:54 Telmisartan's Role in Longevity and Dosing 27:28 Conclusion and Final Thoughts The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode, Regan Archibald breaks down why emotional health isn't “soft”—it's biochemical. He introduces the EPIC triggers (Emotions, Pain, Infections, Chemicals) and focuses on how emotions leave a measurable chemical trail that can either support health or accelerate inflammation. Using examples like anger increasing inflammatory signaling (including IL-6) and gratitude/joy supporting nitric oxide and vascular function, Regan explains how repeated emotional patterns can rewire the brain, shape immune behavior, and even override diet, exercise, and supplements if left unmanaged. The takeaway: practice the pause, choose your response, and build gratitude and connection on purpose. Consistency in emotional regulation can shift physiology toward resilience, recovery, and better long-term health.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
A review by the U.S. Food and Drug Administration (FDA) identified 51 PFAS in 1,744 cosmetic products. Among the 25 most-used PFAS, 19 lacked sufficient safety data for assessment The most common PFAS in European makeup were polytetrafluoroethylene (PTFE) in 26% of PFAS-positive products and perfluorodecalin in 22%, both used to soften skin In a 2021 study, researchers discovered that 82% of waterproof mascaras and over 60% of tested lipsticks and foundations contained high levels of fluorine, indicating the presence of hidden PFAS Several top brands like Urban Decay, Inglot, L'Oréal, Maybelline, Burt's Bees, and Bare Minerals have faced lawsuits or investigations for PFAS contamination despite being marketed as "natural" or "clean" While the FDA lacks a national ban, U.S. states are now leading the shift toward PFAS-free beauty products — nine states have passed or scheduled bans on intentionally added PFAS in cosmetics through 2032
Kathleen Sanzo, J.D. is Co-Chair of Morgan Lewis' life sciences industry team. She centers her practice on regulatory and compliance issues connected to U.S. Food and Drug Administration (FDA)-regulated products. She leads and counsels clients on all legal and regulatory issues concerning food, dietary supplements, and cosmetic product manufacture, approval, marketing, and distribution; food, drug, and device compliance and enforcement matters; and consumer product issues regulated by the U.S. Consumer Product Safety Commission and state enforcement agencies, among other areas. A frequent author and co-author on publications related to FDA matters, Kathleen regularly speaks on these issues at industry events. She serves as Vice Chair of the Consumer Product Regulation Committee of the American Bar Association Section of Administrative Law and Regulatory Practice, and is a member of the Food and Drug Law Institute's Medical Products Committee. In this episode of Food Safety Matters, we speak with Kathy [32:33] about: Why FDA chose a voluntary approach to phasing out synthetic food dyes, the implications of this approach, and industry's response Why state-level food additive restrictions are outpacing federal action How the emerging patchwork of state laws creates significant operational and legal challenges for food manufacturers nationwide The expected supply chain impacts of phasing out synthetic dyes The legal risks companies face, from state enforcement to labeling, false advertising claims, and product liability How companies can prepare by monitoring legislation, securing dependable ingredient suppliers, updating labels, and planning consumer communication How state actions on additives may influence consumer expectations, spur industry innovation, and shape food policy over the next decade. News and Resources News FDA Releases Human Foods Program Priority Deliverables and Guidance Agenda for 2026 [5:48] FDA Testing Pinpoints Contaminated Ingredient in Infant Botulism Outbreak [17:44] EFSA Sets Safety Thresholds for Cereulide Toxin in Infant Formula [19:43] EFSA to Advise on Cereulide Levels in Infant Formula Following Global Recall UK Mother's Allegation that Recalled Nestlé Formula Sickened her Baby is Unconfirmed Experts Share Lessons from a Successful Listeria 'Seek and Destroy' Process [23:36] FDA to Hold Virtual Public Meeting on Food Allergen Thresholds, Releases Event Materials [29:44] Sponsored by: CINTAS We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04
In this episode of Ageless Future, Cade Archibald challenges the common view of muscle as merely cosmetic or mechanical, revealing instead that skeletal muscle functions as a powerful endocrine organ. He explains how contracting muscle releases signaling molecules called myokines that communicate with the brain, liver, immune system, and fat tissue—regulating metabolism, reducing inflammation, improving insulin sensitivity, and supporting cognitive health. Cade highlights why muscle is the body's largest glucose “sink,” making resistance training one of the most effective strategies for diabetes prevention and reversal. He also dives into the dangers of sarcopenia, emphasizing that muscle loss is not just weakness but a systemic breakdown that accelerates aging and increases vulnerability across every major body system. The episode closes with practical takeaways on preserving strength, building resilience, and treating muscle as one of the most essential foundations of longevity.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51 "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12
In this episode of Ageless Future, Cade Archibald reframes aging as a bioenergetic problem—not simply “wear and tear” or the passage of time. He explains how mitochondrial dysfunction can quietly precede chronic disease through declining ATP production, rising oxidative stress (ROS), and increasingly inefficient cellular signaling, setting the stage for issues like neurodegeneration, cardiometabolic disease, and autoimmune/inflammatory disorders. Cade highlights how mitochondria act as intelligent signaling hubs that help the body adapt to stress, why symptoms often appear before labs look abnormal, and how restoring energy can unlock repair, detoxification, hormone balance, and immune stability. He closes with practical “mitochondria-charging” strategies—recovery, sleep, heat/cold exposure, red light, and foundational habits—challenging listeners to prioritize restoration to restore health.AGELESS FUTURE:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD, MS, from Johns Hopkins discusses this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS. Related Content: The US Food and Drug Administration's Regulation of Mifepristone Politics, Science, and the Future of FDA Drug Regulation
Fluoridated water has shaped U.S. dental policy since the 1940s, when officials began adding fluoride to public water supplies in an effort to reduce childhood cavities.1 As of 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that 72.3% of Americans on community water systems (about 62.8% of the entire population) received fluoridated water,2 making systemic exposure nearly unavoidable. Mounting evidence now shows that fluoride offers little measurable benefit for dental health while introducing significant risks, particularly for children. Many countries, including Germany, Sweden, and the Netherlands, have already abandoned water fluoridation.3 In the U.S., Utah and Florida recently became the first states to ban the practice, and similar bills are emerging elsewhere.4 However, in places where fluoride is not added to tap water, fluoride supplements are prescribed for infants and children. Recently, the U.S. Food and Drug Administration (FDA) announced it is taking action to restrict the use of these prescription fluoride supplements, following a directive from the Make America Healthy Again (MAHA) Commission to reassess their safety and effectiveness.5
"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article: A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14 "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01
This episode covers: • Nano CBD Pain Relief Without Cognitive Side Effects A new nano-micelle formulation of CBD called CBD-IN delivers fast, non-addictive pain relief in mice without memory issues, motor impairment or the usual cannabinoid “fog.” Because it crosses the blood brain barrier and directly targets hyperactive pain circuits, it sidesteps many opioid-type drawbacks. Dave explains why precision-designed cannabinoids could reshape chronic pain treatment and longevity support. Source: https://www.sciencedaily.com/releases/2025/11/251117095652.htm • Moderate Calorie Restriction Slows Biological Aging A long-term trial from the National Institute on Aging found that cutting calories by about 12% over two years slowed the pace of aging — measured by methylation clocks and metabolic markers — in lean and mildly overweight adults alike. Dave breaks down why small, manageable dietary tweaks can deliver big longevity gains, without crash dieting or extreme fasting. Source: https://www.nia.nih.gov/news/cutting-calories-may-slow-pace-aging-healthy-adults • FDA Approves AI-Guided Robotic Surgery Trials for Alzheimer's The U.S. Food and Drug Administration (FDA) has granted IDE approval for the first robotic microsurgical study targeting early stage Alzheimer's disease using AI and deep imaging. The trial uses adaptive robotics to target deep brain lymphatic pathways, potentially clearing amyloid/tau deposits with surgical precision. Dave explains why this signals a new era in neurodegeneration – moving from drug-only to machine-assisted brain repair. Source: https://www.mmimicro.com/ide-approval-for-first-robotic-microsurgery-alzheimers-study/ • Antibiotic Reprograms Gut Bacteria to Produce Anti-Aging Molecules Researchers demonstrated that the veterinary antibiotic cephaloridine can reprogram gut microbes to secrete colanic acid — a molecule linked to better mitochondrial health, reduced gut permeability and improved cholesterol/insulin balance in mice. Dave explores how this could evolve into a pipeline of engineered probiotics that act as internal “longevity factories.” Source: https://newatlas.com/aging/antibiotic-longevity-microbiome/ (link remains unchanged) • Klotho: The Longevity Protein Nears Clinical Reality The longevity protein Klotho, known for clearing toxic by-products, calming inflammation and protecting brain/organ networks, is now advancing toward human trials via injectables, oral formats and gene therapy. Dave explains why Klotho is shaping up as a foundational target for next-gen age-reversal strategies and stacking protocols. Source: https://investingnews.com/longevity-focused-health-fueling-u-s-anti-aging-products-market-projected-to-reach-27-billion-by-2033/ (link remains unchanged) All source links provided for easy reference to the original reporting and research above. This episode is essential listening for fans of biohacking, human performance, functional medicine and longevity who want practical tools from Host Dave Asprey and the latest breakthroughs shaping the future of health. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade gives you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence and conscious living. New episodes are released every Tuesday, Thursday, Friday (audio only) and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: nano CBD, CBD-IN, pain relief research, non opioid pain therapies, chronic pain and aging, caloric restriction aging, methylation clocks, metabolic resilience, AI robotics, Alzheimer's microsurgery, neurotech advancement, microbiome engineering, colanic acid, longevity probiotics, mitochondrial support, Klotho protein, anti aging gene therapy, cellular rejuvenation, longevity news, biohacking updates Thank you to our sponsors! LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser. Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:19 — Story 1: Nano CBD for Pain Relief 1:53 — Story 2: Caloric Restriction and Aging 3:20 — Story 3: AI Robotic Surgery for Alzheimer's 4:50 — Story 4: Microbiome Reprogramming 6:05 — Substack Announcement 7:04 — Story 5: Klotho Longevity Protein 8:39 — Weekly Homework 9:31 — Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2026 Ivy Podcast Discovery LLC
